225 related articles for article (PubMed ID: 4858403)
1. Significance of dopamine receptor activity in dl-p-methoxyamphetamine- and d-amphetamine-induced locomotor activity.
Tseng LF; Loh HH
J Pharmacol Exp Ther; 1974 Jun; 189(3):717-24. PubMed ID: 4858403
[No Abstract] [Full Text] [Related]
2. Effect of angiotensin on the central action of dopamine.
Braszko J; Wiśniewski K
Pol J Pharmacol Pharm; 1976; 28(6):667-72. PubMed ID: 1034924
[TBL] [Abstract][Full Text] [Related]
3. Catalepsy, sedation and hypothermia induced by alpha-methyl-p-tyrosine in the rat. An ideal tool for screening of drugs active on central catecholaminergic receptors.
Papeschi R; Randrup A
Pharmakopsychiatr Neuropsychopharmakol; 1973 May; 6(3):137-57. PubMed ID: 4800160
[No Abstract] [Full Text] [Related]
4. Stimulation of postsynaptic alpha1b- and alpha2-adrenergic receptors amplifies dopamine-mediated locomotor activity in both rats and mice.
Villégier AS; Drouin C; Bizot JC; Marien M; Glowinski J; Colpaërt F; Tassin JP
Synapse; 2003 Dec; 50(4):277-84. PubMed ID: 14556232
[TBL] [Abstract][Full Text] [Related]
5. Antagonism by neuroleptics of abnormal behavior induced by activation of brain dopamine receptors.
Van Rossum JM
Mod Probl Pharmacopsychiatry; 1970; 5():65-7. PubMed ID: 5527171
[No Abstract] [Full Text] [Related]
6. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.
Perrault G; Depoortere R; Morel E; Sanger DJ; Scatton B
J Pharmacol Exp Ther; 1997 Jan; 280(1):73-82. PubMed ID: 8996184
[TBL] [Abstract][Full Text] [Related]
7. The neurosteroid 3 alpha-hydroxy-5 alpha-pregnan-20-one affects dopamine-mediated behavior in rodents.
Khisti RT; Deshpande LS; Chopde CT
Psychopharmacology (Berl); 2002 May; 161(2):120-8. PubMed ID: 11981591
[TBL] [Abstract][Full Text] [Related]
8. Neurochemical and behavioral evidence that Ro 41-9067 is a selective presynaptic dopamine receptor agonist.
Nisoli E; Tonello C; Imhof R; Scherschlicht R; da Prada M; Carruba MO
J Pharmacol Exp Ther; 1993 Jul; 266(1):97-105. PubMed ID: 8101225
[TBL] [Abstract][Full Text] [Related]
9. Effects of buspirone on dopamine dependent behaviours in rats.
Dhavalshankh AG; Jadhav SA; Gaikwad RV; Gaonkar RK; Thorat VM; Balsara JJ
Indian J Physiol Pharmacol; 2007; 51(4):375-86. PubMed ID: 18476392
[TBL] [Abstract][Full Text] [Related]
10. Comparative effects of dl-p-methoxyamphetamine and d-amphetamine on catecholamine release and reuptake in vitro.
Tseng LF; Hitzemann RJ; Loh HH
J Pharmacol Exp Ther; 1974 Jun; 189(3):708-16. PubMed ID: 4843169
[No Abstract] [Full Text] [Related]
11. [Effect of repeated haloperidol and apomorphine administration on the development of tolerance for catalepsy and dopamine receptor hypersensitivity in mice].
Zharkovskiĭ AM; Matvienko OA; Nurk AM
Biull Eksp Biol Med; 1984 Oct; 98(10):444-6. PubMed ID: 6541951
[TBL] [Abstract][Full Text] [Related]
12. A comparison of the effects of d-amphetamine and morphine upon the locomotor activity of mice treated with drugs which alter brain catecholamine content.
Villarreal JE; Guzman M; Smith CB
J Pharmacol Exp Ther; 1973 Oct; 187(1):1-7. PubMed ID: 4746328
[No Abstract] [Full Text] [Related]
13. Effects of d-amphetamine and apomorphine upon operant behavior and schedule-induced licking in rats with 6-hydroxydopamine-induced lesions of the nucleus accumbens.
Robbins TW; Roberts DC; Koob GF
J Pharmacol Exp Ther; 1983 Mar; 224(3):662-73. PubMed ID: 6402587
[TBL] [Abstract][Full Text] [Related]
14. Sensorimotor gating effects produced by repeated dopamine agonists in a paradigm favoring environmental conditioning.
Feifel D; Priebe K; Johnstone-Miller E; Morgan CJ
Psychopharmacology (Berl); 2002 Jul; 162(2):138-46. PubMed ID: 12110991
[TBL] [Abstract][Full Text] [Related]
15. Prefrontal cortical and hippocampal modulation of haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat.
Lipska BK; Jaskiw GE; Braun AR; Weinberger DR
Biol Psychiatry; 1995 Aug; 38(4):255-62. PubMed ID: 8547448
[TBL] [Abstract][Full Text] [Related]
16. The influence of antineoplaston A5 on the central dopaminergic structures.
Juszkiewicz M; Chodkowska A; Burzynski SR; Feldo M; Majewska B; Kleinrok Z
Drugs Exp Clin Res; 1994; 20(4):161-7. PubMed ID: 7813388
[TBL] [Abstract][Full Text] [Related]
17. Potentiation of haloperidol-induced catalepsy by dopamine agonists: possible involvement of central 5-hydroxytryptamine.
Carter CJ; Pycock CJ
Pharmacol Biochem Behav; 1979 Apr; 10(4):475-80. PubMed ID: 572550
[TBL] [Abstract][Full Text] [Related]
18. Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice.
Moreira FA; Guimarães FS
Eur J Pharmacol; 2005 Apr; 512(2-3):199-205. PubMed ID: 15840405
[TBL] [Abstract][Full Text] [Related]
19. Modification of striatal acetylcholine concentration by dopamine receptor agonists and antagonists.
Sethy VH; VAN Woert MH
Res Commun Chem Pathol Pharmacol; 1974 May; 8(1):13-28. PubMed ID: 4847901
[No Abstract] [Full Text] [Related]
20. Pharmacological studies on tetrabenazine-induced excited behaviour of rats pretreated with amphetamine or nialamide.
Scheel-Krüger J; Jonas W
Arch Int Pharmacodyn Ther; 1973 Nov; 206(1):47-65. PubMed ID: 4798103
[No Abstract] [Full Text] [Related]
[Next] [New Search]
